| |
2 years of abatacept treatment
|
6-month follow-up period
|
|---|
|
Day 113
|
Day 477
|
Day 645
|
Day 729
|
Day 85
|
Day 168
|
|---|
|
2–5-year-old cohort
|
|
Anti-GAD+
|
1
|
1
|
0
|
0
|
0
|
0
|
|
Anti-TPO+
|
0
|
0
|
0
|
0
|
0
|
0
|
|
6–17-year-old cohort
| | | | | | |
|
Anti-GAD+
|
0
|
0
|
0
|
1‡
|
0
|
0
|
|
Anti-TPO+†
|
0
|
3
|
1
|
1‡
|
0
|
1
|
- Values in table are number of patients. *Autoantibody positivity was defined as anti-GAD ≥5 IU/mL or anti-TPO ≥60 U/mL. TSH abnormalities were defined as >1.5x ULN, or if baseline was >ULN then >2x baseline value. †One patient had new-onset positive anti-TPO antibodies on Days 477, 645, 729 and Day 168 during the follow-up period. ‡The patients with positive anti-GAD and anti-TPO at Day 729 are different patients. GAD=glutamic acid decarboxylase; TPO=thyroid peroxidase; TSH=thyroid-stimulating hormone; ULN=upper limit of normal
